Arkolith/Insider Trading/BCAX/Form 4

Mazumdar Claire

Chief Executive Officer, DirectorBicara Therapeutics Inc. (BCAX) · full profile →Form 4 · filed May 20, 2026
Net Selling
Open-Market Buys
$0
Open-Market Sells
$301K
Net Open-Market Flow
-$301K
Transactions
4
3 non-derivative · 1 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
May 18, 2026Option exercise(M)15K$3.79$57K377K
May 18, 2026Sell(S)12K$19.96$240K365K
May 18, 2026Sell(S)3K$20.35$61K362K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
May 18, 2026Option exercise(M)15K—$0146K

Transaction Codes

M
Option exercise / conversion
S
Open-market sale

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001628280-26-036885) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML